Trial Profile

A phase I dose finding study of everolimus (RAD001) in elderly patients with acute myeloid leukemia (AML) unfit for intensive induction chemotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Azacitidine
Indications Acute myeloid leukaemia
Focus Adverse reactions; Biomarker

Most Recent Events

14 Feb 2013 Planned number of patients changed from 24 to 40 as reported by ClinicalTrials.gov.
14 Feb 2013 Planned end date changed from 1 Feb 2011 to 1 Jan 2014 as reported by ClinicalTrials.gov.
14 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com